Index
Technical Report Documentation Page
Introduction
Cannabis/Marijuana
Carisoprodol (and Meprobamate)
Cocaine
Dextromethorphan
Diazepam
Diphenhydramine
Gamma-Hydroxybutyrate (GHB, GBL,
and 1,4-BD)
Ketamine
Lysergic acid diethylamide (LSD)
Methadone
Methamphetamine (and Amphetamine)
Methylenedioxymethamphetamine
(MDMA, Ecstasy)
Morphine (and Heroin)
Phencyclidine (PCP)
Toluene
Zolpidem (and Zaleplon, Zopiclone)
Biographical Sketches of Lead
Authors and Main Contributors |
|
The use of psychoactive drugs followed by driving has been an issue
of continual concern to law enforcement officers, physicians, attorneys,
forensic toxicologists and traffic safety professionals in the U.S. and
throughout the world. At issue are methods for identifying the impaired
driver on the road, the assessment and documentation of the impairment
they display, the availability of appropriate chemical tests, and the
interpretation of the subsequent results. A panel of international experts
on drug-related driving issues met to review developments in the field
of drugs and human performance over the last 10 years; to identify the
specific effects that both illicit and prescription drugs have on driving;
and to develop guidance for others when dealing with drug-impaired driving
problems.
This publication is based on the deliberations of the International
Consultative Panel on Drugs and Driving Impairment held in Seattle, WA
in August 2000. This meeting was sponsored by the National Safety Council,
Committee on Alcohol and other Drugs; the State of Washington Traffic
Safety Commission; and the National Highway Traffic Safety Administration.
Delegates represented the fields of psychopharmacology, behavioral psychology,
drug chemistry, forensic toxicology, medicine, and law enforcement experts
trained in the recognition of drug effects on drivers in the field. The
Fact Sheets reflect the conclusions of the Panel and have been designed
to provide practical guidance to toxicologists, pharmacologists, law
enforcement officers, attorneys and the general public on issues related
to drug impaired driving.
Sixteen drugs were selected for review and include over-the-counter
medications, prescription drugs, and illicit and/or abused drugs. The
selected drugs are cannabis/marijuana, carisoprodol, cocaine, dextromethorphan,
diazepam, diphenhydramine, gamma-hydroxybutyrate, ketamine, lysergic
acid diethylamide, methadone, methamphetamine/amphetamine, methylenedioxymethamphetmaine,
morphine/heroin, phencyclidine, toluene, and zolpidem.
The Fact Sheets are based on the state of current scientific knowledge
and represent the conclusions of the panel. They have been designed to
provide practical guidance to toxicologists, pharmacologists, law enforcement
officers, attorneys and the general public to use in the evaluation of
future cases. Each individual drug Fact Sheet covers information regarding
drug chemistry, usage and dosage information, pharmacology, drug effects,
effects on driving, drug evaluation and classification (DEC), and the
panel’s assessment of driving risks. A list of key references and
recommended reading is also provided for each drug. Readers are encouraged
to use the Fact Sheets in connection with the other cited impaired driving-related
texts.
The information provided is uniform for all the Fact Sheets and provides
details on the physical description of the drug, synonyms, and pharmaceutical
or illicit sources; medical and recreational uses, recommended and abused
doses, typical routes of administration, and potency and purity; mechanism
of drug action and major receptor sites; drug absorption, distribution,
metabolism and elimination data; blood and urine concentrations; psychological
and physiological effects, and drug interactions; drug effects on psychomotor
performance effects; driving simulator and epidemiology studies; and
drug recognition evaluation profiles. Each Fact Sheet concludes with
general statements about the drugs’ ability to impair driving performance.
The authors strongly believe that all the above information needs to
be taken into account when evaluating a drug.
Case interpretation can be complicated by a number of factors and one
of the main limitations of the Fact Sheets is that they primarily relate
to single drug use. Other factors which influence the risk of effects
on driving for any drug include the dose, the dosage frequency, acute
and residual effects, chronic administration, route of administration,
the concentration of the drug at the site of action, idiosyncrasies of
metabolism, drug tolerance or hypersensitivity, and the combined effects
of the drug with other drugs or alcohol, to name but a few.
Individual Fact Sheets
- Cannabis/Marijuana
- Carisoprodol (and Meprobamate)
- Cocaine
- Dextromethorphan
- Diazepam
- Diphenhydramine
- Gamma-Hydroxybutyrate (GHB, GBL, and 1,4-BD)
- Ketamine
- Lysergic acid diethylamide (LSD)
- Methadone
- Methamphetamine (and Amphetamine)
- Methylenedioxymethamphetamine (MDMA, Ecstasy)
- Morphine (and Heroin)
- Phencyclidine (PCP)
- Toluene
- Zolpidem (and Zaleplon, Zopiclone)
Lead Authors:
Fiona Couper, Ph.D. and Barry Logan, Ph.D.
Main contributors:
Michael J Corbett, Ph.D., Laurel Farrell, BS, Marilyn Huestis Ph.D.,
Wayne Jeffrey, BS, Jan Raemakers Ph.D.
Other delegates to the consensus conference:
Marcelline Burns, Ph.D.; Yale Caplan, Ph.D.; Dennis Crouch, BS, MBA;
Johann De Gier, Ph.D.; Olaf Drummer Ph.D.; Kurt Dubowski, Ph.D.; Robert
Forney Jr., Ph.D.; Bernd Freidel, M.D.; Manfred Moeller, Ph.D.; Thomas
Page, BA; Lionel Raymon, Pharm.D., Ph.D., Wim Riedel, Ph.D.; Laurent
Rivier, Ph.D.; Annemiek Vermeeren, Ph.D. and H. Chip Walls BS. Other
participants included James F. Frank, Ph.D. from the NHTSA Office of
Research & Technology; Sgt. Steven Johnson of the Washington State
Patrol; Capt. Chuck Hayes of the Oregon State Patrol; and Sgt. Douglas
Paquette of the New York State Police.
Disclaimer
The information contained in the Drugs and Human Performance Fact Sheets
represents the views of the contributors and not necessarily those of
their place of employment or the National Highway Traffic Safety Administration. |